Q3 2024 EPS Estimates for Edwards Lifesciences Co. Raised by Analyst (NYSE:EW)

Edwards Lifesciences Co. (NYSE:EW) – Stock analysts at Leerink Partnrs boosted their Q3 2024 EPS estimates for shares of Edwards Lifesciences in a research note issued on Friday, April 26th. Leerink Partnrs analyst M. Kratky now forecasts that the medical research company will post earnings per share of $0.71 for the quarter, up from their prior estimate of $0.70. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.76 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences’ Q4 2024 earnings at $0.71 EPS and Q1 2025 earnings at $0.72 EPS.

Other equities analysts also recently issued reports about the stock. Citigroup raised their price target on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 3rd. Evercore ISI lowered their target price on Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a report on Friday. Stifel Nicolaus increased their price target on Edwards Lifesciences from $83.00 to $85.00 and gave the company a “hold” rating in a report on Friday. StockNews.com lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, March 20th. Finally, Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research note on Thursday, March 7th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $92.71.

Edwards Lifesciences Trading Down 1.8 %

Shares of EW stock opened at $86.43 on Monday. Edwards Lifesciences has a fifty-two week low of $60.57 and a fifty-two week high of $96.12. The firm has a market capitalization of $52.02 billion, a P/E ratio of 37.25, a PEG ratio of 4.29 and a beta of 1.05. The stock’s fifty day moving average is $90.28 and its two-hundred day moving average is $78.95. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.40 and a current ratio of 3.38.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. The business had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Edwards Lifesciences had a return on equity of 23.34% and a net margin of 23.01%.

Institutional Investors Weigh In On Edwards Lifesciences

Hedge funds have recently added to or reduced their stakes in the business. Nordea Investment Management AB boosted its stake in shares of Edwards Lifesciences by 1,224.1% in the 4th quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company’s stock valued at $123,261,000 after buying an additional 1,488,791 shares during the period. Telos Capital Management Inc. raised its holdings in Edwards Lifesciences by 158.2% in the fourth quarter. Telos Capital Management Inc. now owns 91,405 shares of the medical research company’s stock valued at $6,970,000 after acquiring an additional 56,000 shares in the last quarter. Arlington Trust Co LLC lifted its stake in Edwards Lifesciences by 5,092.4% in the fourth quarter. Arlington Trust Co LLC now owns 12,306 shares of the medical research company’s stock worth $938,000 after acquiring an additional 12,069 shares during the last quarter. Versor Investments LP grew its holdings in Edwards Lifesciences by 83.3% during the 3rd quarter. Versor Investments LP now owns 4,496 shares of the medical research company’s stock worth $311,000 after acquiring an additional 2,043 shares in the last quarter. Finally, HealthInvest Partners AB purchased a new stake in shares of Edwards Lifesciences in the 4th quarter valued at approximately $1,587,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the completion of the sale, the chief financial officer now owns 19,248 shares in the company, valued at approximately $1,506,925.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, SVP Robert W.A. Sellers sold 12,210 shares of the stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $87.00, for a total transaction of $1,062,270.00. Following the sale, the senior vice president now owns 13,087 shares of the company’s stock, valued at $1,138,569. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the transaction, the chief financial officer now directly owns 19,248 shares of the company’s stock, valued at approximately $1,506,925.92. The disclosure for this sale can be found here. In the last three months, insiders have sold 194,004 shares of company stock valued at $17,166,254. Company insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.